艾力斯 (688578)
Shanghai Allist Pharmaceuticals Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai Allist Pharmaceuticals Co., Ltd.
Listing Date2020-12-02
Issue Price22.73RMB
Registered Capital4500010k RMB
Legal RepresentativeDu Jinhao
Registered AddressNo. 268, Lingxiaohua Road, Zhoupu Town, Pudong New District, Shanghai
IndustryChemical Pharmaceuticals
Main BusinessThe issuer is an innovative pharmaceutical company focused on the field of oncology treatment. It has currently established a rich R&D pipeline in the area of small molecule targeted drugs for non-small cell lung cancer.
Company ProfileThe company possesses extensive experience in innovative drug R&D and regulatory registration, and has achieved significant R&D results. In July 2012, the company's self-developed Allisartan Isoproxil, the first domestic Class 1.1 new antihypertensive drug in the sartan category, obtained the new drug certificate from the former China Food and Drug Administration (CFDA). This product is also the only antihypertensive drug in the angiotensin II receptor antagonist class that is independently developed by a domestic enterprise and possesses independent intellectual property rights.
Stock Details
1. Key Indicators
- Total Shares(W): 45000.00
- Circulating A-Shares(W): 45000.00
- Earnings Per Share(RMB): 3.5900
- Net Assets Per Share(RMB): 14.4418
- Operating Revenue(W RMB): 373301.77
- Total Profit(W RMB): 188870.08
- **Net Profit Attributable to Parent(W RMB) **: 161577.66
- Net Profit Growth Rate(%): 52.01
- Weighted Return on Equity(%): 27.9200
- Operating Cash Flow Per Share(RMB): 3.8450
- Undistributed Profit Per Share(RMB): 5.4048
- Capital Reserve Per Share(RMB): 7.2873
2. Main Business
The main business covers:
- R&D and sales of innovative drugs in the field of oncology treatment.
3. Company Basic Information
- Company Name: Shanghai Allist Pharmaceuticals Co., Ltd.
- Listing Date: 2020-12-02
- Industry: Pharmaceutical Manufacturing
- Address: 5th Floor, Building 1, No. 1227 Zhangheng Road, No. 1118 Harley Road, China (Shanghai) Pilot Free Trade Zone
- Website: https://www.allist.com.cn
- Company Profile: The company was established through the overall transformation of Shanghai Allist Pharmaceutical Technology Co., Ltd., focusing on the R&D of innovative drugs in the field of oncology treatment, technology transfer, and related consulting services.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shanghai Qiaoke Enterprise Development Co., Ltd. | General Legal Person | 14477.68 | 32.17 |
| 2 | Shanghai Aixiang Enterprise Development Center (Limited Partnership) | General Legal Person | 2252.07 | 5.00 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 2094.71 | 4.65 |
| 4 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 859.51 | 1.91 |
| 5 | E Fund SSE STAR Market 50 Constituents ETF | Fund | 828.14 | 1.84 |
| 6 | ChinaAMC SSE STAR Market 50 Constituents ETF | Fund | 796.44 | 1.77 |
| 7 | Morgan Emerging Power Hybrid Securities Investment Fund Class A | Fund | 251.22 | 0.56 |
| 8 | Morgan China Advantage Securities Investment Fund Class A | Fund | 84.72 | 0.19 |
| 9 | ICBC Credit Suisse Strategic Transformation Theme Stock Securities Investment Fund Class A | Fund | 83.09 | 0.18 |
| 10 | Morgan Technology Frontier Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 81.92 | 0.18 |
5. Concept Sectors
- Innovative Drugs
- Margin Trading & Securities Lending
- High-Performance Stocks
- Heavily Held by Funds
- Hundred-Yuan Stocks
- Non-Cyclical Stocks
- SSE Governance
- SSE 380
- Mid-Cap Growth
- SZSE Growth
- Tencent Ji'an
- STAR Market 50
- Innovation 100
- STAR Market Biotech
- Emerging Market Index
Remarks
- Data update date: 2025-11-04
- Data source: Public Market Information